Rg3 Shenyi Capsule - Anti-cancer agent

The Rg₃ Shenyi Capsule is one of the leading products of the company. It was developed by the company and it therefore possesses the intellectual property rights. The product has a high direct inhibition rate of many transferable cancers. This can be up to 90%, and the inhibition rate of the metastasis of lung and liver cancer is 70%-80%. It is the first product to be designated a ‘First national Grade 1 anti-cancer traditional Chinese medicine?/span>

The Rg₃ Shenyi Capsule is a newly developed anti-tumor medicine pioneered by Chinese national scientists. It is the only remedy in clinical application used to restrain tumor transfer, tumor recurrence and tumor growth.  Long term use of RG₃ Shenyi Capsule is beneficial for the patient, through the strengthening of the immune function, living condition and extending the survival time.

Purpose:

The reason why the cancer is so hard to cure is because the easy transfer of the tumor cells. If the tumor only grows at the original location, most cancer could be healed. So, it is no wonder that the anti-transfer remedy is becoming the important core for the anti-tumor remedy research.

The major ingredient of Shenyi Capsule Rg₃ is proved to have significant effects during the twenty years of research in China, Japan, Russia and German. Because of the difficulty in production, it was only in laboratory use, but not in clinic application. Chinese national scientists have studied for so many years to conquer this problem; this led to the birth of new remedy - RG₃ Shenyi Capsule.

Soon after the Shenyi Capsule came onto the market, it gained great attention from the experts and media. CCTV, People Daily, Guangming Daily, Scientific Daily etc, had great praise about the product. At the same time, the biggest Asian tumor hospital - China Medical Academy Tumor Hospital undertook further research programs concerning the Shenyi Capsule. Shenyi Capsule was evaluated as the important new product in 2000 by the National Science and Technology Bureau.

Mechanisms:

Taken orally, the tumor restrain rate is 60 percent and the transfer restraint rate is 60 to 70 percent in lung cancer and liver cancer. Rg₃ can regulate the immune function, improve the effect of radio-treatment, decrease the decline of leukocyte, and hair lose. Research indicates the direct restrain rate for the highly transferring tumor is more than 90 percent. Rg₃ can break off the combination between tumor cells and fiber protein; restrain the growth of tumor endothelium cells and blood vessel shaping. Metabolism kinetics research indicates the good absorption results. The absorption apex could be detected 15 - 30 minutes post operation, the target concentration in blood would come to the maximum value about 1.0 to 1.5 hour post operation, the half life is 4.84 ?/span>1.41 hr. The toxin research indicates there were no poisonous damage, no reproductive damage, no abnormal damage and no mutation inclination.
    

It is licensed for sale in China by the SFDA (State Food and Drug Administration) and will be soon launched worldwide.

[ Home ] [ Public information ] [ Doctors 1 ] [ Doctors 2 ] [ Doctors 3 ] [ Specification ] [ Patients 1 ] [ Patients 2 ] [ Patients 3 ]      

Send mail to webmaster@yatai.com with questions or comments about this web site.
Copyright ?2004 Jilin Yatai (Group) Co., Ltd.
Last modified: Sunday, 19. December 2004